Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Rosenberg Matthew Hamilton

Rosenberg Matthew Hamilton boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 15.3% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 566 shares of the medical research company’s stock after acquiring an additional 75 shares during the period. Rosenberg Matthew Hamilton’s holdings in Thermo Fisher Scientific were worth $311,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in TMO. Mystic Asset Management Inc. bought a new stake in Thermo Fisher Scientific in the fourth quarter valued at $29,000. Advanced Research Investment Solutions LLC lifted its position in Thermo Fisher Scientific by 213.3% in the 1st quarter. Advanced Research Investment Solutions LLC now owns 47 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 32 shares during the last quarter. Adirondack Trust Co. bought a new position in Thermo Fisher Scientific in the 2nd quarter worth about $34,000. Oliver Lagore Vanvalin Investment Group bought a new stake in shares of Thermo Fisher Scientific during the first quarter valued at approximately $38,000. Finally, Lloyd Advisory Services LLC. boosted its position in shares of Thermo Fisher Scientific by 294.1% during the first quarter. Lloyd Advisory Services LLC. now owns 67 shares of the medical research company’s stock worth $40,000 after buying an additional 50 shares during the period. 86.50% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Jim P. Manzi sold 814 shares of the stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $597.24, for a total value of $486,153.36. Following the completion of the sale, the director now directly owns 15,807 shares of the company’s stock, valued at $9,440,572.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Stephen Williamson sold 12,300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $603.48, for a total transaction of $7,422,804.00. Following the completion of the sale, the chief financial officer now directly owns 43,944 shares in the company, valued at approximately $26,519,325.12. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jim P. Manzi sold 814 shares of the stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $597.24, for a total value of $486,153.36. Following the completion of the transaction, the director now owns 15,807 shares in the company, valued at approximately $9,440,572.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,397 shares of company stock worth $33,012,754. 0.43% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on TMO. SVB Leerink raised their price target on Thermo Fisher Scientific from $630.00 to $650.00 and gave the company an “outperform” rating in a report on Friday, July 29th. Barclays lowered their price objective on shares of Thermo Fisher Scientific from $685.00 to $595.00 and set an “overweight” rating on the stock in a research note on Monday, September 12th. Morgan Stanley increased their price target on Thermo Fisher Scientific from $670.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, July 29th. Finally, Credit Suisse Group started coverage on Thermo Fisher Scientific in a research note on Wednesday, August 24th. They issued a “neutral” rating and a $675.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $656.56.

Thermo Fisher Scientific Trading Down 1.0 %

Shares of TMO opened at $520.29 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 0.69. Thermo Fisher Scientific Inc. has a 1-year low of $497.83 and a 1-year high of $672.34. The stock has a market capitalization of $203.84 billion, a P/E ratio of 27.69, a P/E/G ratio of 1.64 and a beta of 0.85. The business’s 50-day moving average price is $567.60 and its 200 day moving average price is $558.21.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last released its quarterly earnings results on Thursday, July 28th. The medical research company reported $5.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.92 by $0.59. Thermo Fisher Scientific had a net margin of 17.37% and a return on equity of 24.36%. The business had revenue of $10.97 billion for the quarter, compared to analyst estimates of $9.95 billion. During the same quarter in the previous year, the business earned $5.60 earnings per share. The firm’s revenue was up 18.3% compared to the same quarter last year. Analysts expect that Thermo Fisher Scientific Inc. will post 22.92 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 14th. Investors of record on Thursday, September 15th will be given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 0.23%. The ex-dividend date is Wednesday, September 14th. Thermo Fisher Scientific’s payout ratio is 6.39%.

About Thermo Fisher Scientific

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.